1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAdvancing the Use of Genomic Information Into Clinical Care is sponsored by National Institutes of Health (NIH). This topic promotes research that improves health by generating genomic evidence and/or implementing genomic findings into healthcare, including preventive strategies for managing patients with genomic risk.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Advancing the Use of Genomic Information Into Clinical Care | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Advancing the Use of Genomic Information Into Clinical Care When beginning your next investigator-initiated application, consider the following NIH highlighted topic. The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs).
This is not a notice of funding opportunity (NOFO). Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants. gov .
Learn how to interpret and use Highlighted Topics . Post Date: September 10, 2025 Expiration Date: August 29, 2027 This topic seeks to promote research that improves health by generating genomic evidence and/or implementing genomic findings into healthcare. Despite substantial evidence showing genomic variants increase risk for numerous diseases, evidence is limited that using genomic results improves short and long-term outcomes.
This topic addresses this gap by encouraging studies on the impact of genomic information on clinical outcomes while also encouraging research on the most effective methods for implementation of evidence-based genomic medicine interventions into healthcare. Exemplary topics include: 1.
Generating Genomic Medicine Evidence: Pilot Studies: Testing whether use of genomic information improves short-term clinical outcomes or cost-effectiveness, with potential for follow-up to assess long-term impact and real-world application. Outcome Metrics: Developing metrics to evaluate clinical utility, including patient outcomes and cost-effectiveness. Generalizability: Ensuring findings apply across populations and settings.
2. Integrating Genomic Evidence into Clinical Care: Implementation Research: Investigating facilitators and barriers to implementing genomic medicine across a wide range of clinical settings. Frameworks for Study: Identifying, assessing, and applying implementation science frameworks to the study of genomic medicine.
Integration Strategies: Developing and researching strategies to integrate genomic evidence into clinical workflows in ways that optimize health outcomes. Preventive Strategies: Researching preventive strategies to the management of patients with genomic risk while optimizing access, risk, cost, and convenience. 3.
Developing and/or expanding resources relevant to genomic medicine: Clinical resources: defining relevance of genes and variants, developing, implementing, and maintaining genomic-based clinical tools and services for use in genomic medicine.
Translational resources: advancing the creation of repositories of curated multi-omic genetic data to facilitate the investigation of genetic influences on traits, diseases and treatments, enabling better disease prediction, prevention, and therapy strategies.
In summary, this topic promotes innovative research that advances the implementation of genomic information in clinical care, ensuring its benefits are broadly accessible and effectively integrated into routine healthcare. Central Scientific Contact: National Human Genome Research Institute (NHGRI) NHGRI is interested in all of the exemplary topics above.
National Institute of Allergy and Infectious Diseases (NIAID) NIAID is interested in supporting projects that focus on research that advance the use of genomic evidence (human, microbiome, and/or pathogen) to improve clinical diagnosis, care and resolution of infectious diseases, including HIV/AIDS; immunologic and allergic diseases, or organ transplantation; and other areas arising that are relevant to NIAID's scientific mission.
National Institute on Drug Abuse (NIDA) NIDA is interested in studies defining the relevance of genes and gene variants, developing and implementing and maintaining genomic based tools for substance use and addiction.
National Institute of Neurological Disorders and Stroke (NINDS) National Institute of Nursing Research (NINR) The NINR leverages a person-centered holistic nursing perspective to support rigorous solution-oriented research conducted by scientists from any discipline. NINR leads discoveries of innovative systems and models of care, breakthroughs in disease prevention and health promotion, and advances in population and community health.
Our research empowers individuals, families, communities, and populations to optimize their health and well-being. NINR supports research that addresses health differences, intervenes on the conditions in which people live, uses multilevel approaches to prevent disease and promote health, and implements clinical and organizational solutions to maximize positive outcomes of care delivery.
Mary Elizabeth Bowen, PhD Office of Research on Women's Health (ORWH) The areas of interest of the Office of Autoimmune Disease Research in the Office of Research on Women’s Health (OADR-ORWH) include: Develop and use genomic data resources for multilevel approaches to diagnose, prevent, and treat chronic conditions in women. Translate genetic research advancements in women's health across the life course.
Accelerating scientific discovery, developing data science and computational tools to integrate the interactions of genetics with environmental factors for diagnosis, treatment, prevention, and cures, and enhancing health for people with autoimmune disease. This office does not award grants. Applications must be relevant to the objectives of at least one of the participating NIH Institutes and Centers listed in this topic.
Elena Gorodetsky, M. D. , Ph.
D. Victoria Shanmugam, MBBS, MRCP, FACR, CCD National Institute of Dental and Craniofacial Research (NIDCR) Lorena Baccaglini, DDS, MS, PhD, NE-CPhT National Cancer Institute (NCI) Sarah Kalia, PhD, SM, ScM For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Investigator-initiated applications are welcomed. This is a highlighted topic, not a NOFO; apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants. Confirm the full requirements in the official notice before applying.
Applications for Advancing the Use of Genomic Information Into Clinical Care are due August 29, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Advancing the Use of Genomic Information Into Clinical Care is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
NIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read articleNIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read article